Pooled Analysis of Elderly Patients with Non-small Cell Lung Cancer Treated with Front Line Docetaxel/Gemcitabine Regimen: The Hellenic Oncology Research Group Experience

Pallis, Athanasios; Polyzos, Aris; Boukovinas, Ioannis; Agelidou, Athina; Lamvakas, Lambros; Tsiafaki, Xanthi; Agelidou, M.; Pavlakou, Georgia; Chandrinos, Vassilis; Kakolyris, S; Christophyllakis, C.; Kentepozidis, Nikolaos; Giassas, Stelios; Androulakis, Nikolaos; Agelaki, Sofia; Georgoulias, Vassilis

doi:10.1097/jto.0b013e31816b4b32

Cited by 26 publications

(17 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, because some studies define elderly status as 70 and older [27][28][29], we examined whether response, PFS, or ECOG performance status differed among those between 65 and 69 (n = 12) and those over 70 (n = 31). Response rate differed nonsignificantly, at 25% for the younger group and 16.1% for the older group, although the proportion of patients with performance status of 2 was nearly identical in both groups, at about 25%.…”

Section: Elderly Statusmentioning

confidence: 99%

A phase II trial of pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIB/IV non-small cell lung cancer

et al. 2009

View full text Add to dashboard Cite

Section: Elderly Statusmentioning

confidence: 99%

A phase II trial of pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIB/IV non-small cell lung cancer

et al. 2009

View full text Add to dashboard Cite

“…Chemotherapy was well tolerated but the incidence of grade 3-4 mucositis and diarrhea was significantly higher in elderly patients compared to younger patients. Multivariate analysis revealed that PS (p=0.0001) and Stage (p= 0.0001) but not the age were significant independent factors in the hazard of death [9].…”

Section: Single Agent Vs Platinum-based Doubletmentioning

confidence: 99%

“…Elderly patients with advanced non-squamous NSCLC should be tested for EGFR mutation and ALK rearrangement for ALK positive [9,12].…”

Section: Single Agent Vs Platinum-based Doubletmentioning

confidence: 99%

Reasonable Choices for Cytotoxic or Cytostatic Treatment in Elderly Advanced Non-Small Cell Lung Cancer Patients

Zarogoulidis¹

2015

Lung Dis Treat

View full text Add to dashboard Cite

“…While it is true that the incidence of age-related organ dysfunction and the development of comorbid conditions increase abruptly between 70 and 75 years of age (5), the clinical significance of the relationship between age and comorbid conditions is complex in patients with cancer (6) and it has been suggested that chronological age is not a valid criterion on which to base treatment decisions in NSCLC (7). Clinical trials that have investigated the effects of cytotoxic chemotherapy in unselected elderly patients have reported modest improvements in outcomes (8)(9)(10)(11), while an analysis of two large, randomised trials of adjuvant/palliative chemotherapy for NSCLC found that the age of the patient did not influence overall survival (OS), but that the presence of comorbid conditions was linked with poorer survival (7).…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer

Merimsky¹,

Cheng²,

et al. 2012

Oncology Reports

View full text Add to dashboard Cite

Abstract. TaRceva LUng cancer Survival Treatment (TRUST)was an open-label, phase IV study of advanced non-small cell lung cancer (NSCLC). Patients failing or unsuitable for chemotherapy or radiotherapy received erlotinib 150 mg/day until progression. We examined a subpopulation of elderly patients (≥70 years) receiving first-line erlotinib (n=485) in TRUST. In this subpopulation, disease control rate (n=356 with best response data available) was 79% (vs. 69% for the overall TRUST population; P<0.0001); median progressionfree survival (PFS) was 4.57 months [95% confidence interval (CI), 3.68-5.22]; median overall survival (OS) was 7.29 months (95% CI, 6.27-8.67); and one-year survival, was 36.6%. PFS and OS were significantly longer in patients developing rash, compared to those without, and in those with good performance status (PS; 0/1), compared to poor PS (≥2). Eighty-seven subpopulation patients (18%) had an erlotinib-related AE; other than the protocol-defined frequent adverse events (AEs); 4% had a grade ≥3 erlotinib-related AE, 7% had an erlotinibrelated serious AE. In the subpopulation, dose reductions were required in 27%, most (97%) were reductions to 100 mg/ day; treatment was discontinued in 10%, and one death was associated with treatment-related toxicity (<1%). Erlotinib was effective and well-tolerated and may be considered for elderly patients with advanced NSCLC who are unsuitable for standard first-line chemotherapy or radiotherapy. IntroductionThe incidence of non-small cell lung cancer (NSCLC) increases with age, with 60% of cases arising in patients over 60 years of age, and 30-40% in patients of 70 years or older (1,2). In developed countries the median age of diagnosis for advanced disease is 68 years (3), but this has increased notably over the last 3 decades. Consequently, the age of the patient is often a major factor for physicians considering treatment options for patients with advanced NSCLC. Elderly patients are often denied therapy, prematurely discontinued and excluded from clinical trials because of the perception that they are less able to tolerate cytotoxic chemotherapy than younger patients, and are more likely to suffer toxic effects that adversely affect their quality of life (4). Physicians may be concerned that age-related impairment in renal or hepatic function could exacerbate the toxic effects of chemotherapy, and that the presence of comorbidities could reduce the capacity of their elderly patients to tolerate such effects. While it is true that the incidence of age-related organ dysfunction and the development of comorbid conditions increase abruptly between 70 and 75 years of age (5), the clinical significance of the relationship between age and comorbid conditions is complex in patients with cancer (6) and it has been suggested that chronological age is not a valid criterion on which to base treatment decisions in NSCLC (7). Clinical trials that have investigated the effects of cytotoxic chemotherapy in unselected elderly patients have reported modest improvements i...

show abstract

Pooled Analysis of Elderly Patients with Non-small Cell Lung Cancer Treated with Front Line Docetaxel/Gemcitabine Regimen: The Hellenic Oncology Research Group Experience

Abstract: The docetaxel/gemcitabine regimen has a comparable efficacy and tolerance in young (< 70 years) and elderly (> or = 70 years) patients.

Cited by 26 publications

References 25 publications

A phase II trial of pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIB/IV non-small cell lung cancer

A phase II trial of pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIB/IV non-small cell lung cancer

Reasonable Choices for Cytotoxic or Cytostatic Treatment in Elderly Advanced Non-Small Cell Lung Cancer Patients

Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer

Contact Info

Product

Resources

About